Conn. Woman Says Novo Nordisk Failed to Warn of Ozempic’s Gastrointestinal Risks

HARTFORD, Conn. — A woman who says she developed gastroparesis after taking the GLP-1RA drug Ozempic for five months has sued Novo Nordisk in Connecticut federal court, alleging it knew by 2010 the weight loss drug can cause severe gastrointestinal injuries, yet failed to warn doctors and the public of that risk.

In a Dec. 31 complaint filed in the U.S. District Court for the District of Connecticut, the plaintiff says published medical literature shows that GLP-1 slows gastric emptying, and as a result can cause abdominal pain, obstruction of the intestines, vomiting and diarrhea.

“Because the risk of …